🔗 Permalink

Inventor profile of:

Rik RADEMAKER

City:

Utrecht

Country:

Netherlands

Published Applications:

Last publication date:

2025-11-06

Top Assignees for applications by Rik RADEMAKER

The entities that hold a legal rights for patent applications filed by inventor RADEMAKER Rik:

H. LUNDBECK A/S 11 Valby, Denmark
GENMAB A/S 9 Copenhagen V, Denmark
BioNTech SE 8 Mainz, Germany
GENMAB A/S 6 Valby, Denmark
GENMAB A/S 3 Copenhagen, Denmark
GENMAB A/S 1 Copenhagen K, Denmark

Recent patent applications by RADEMAKER Rik

Rik RADEMAKER from Utrecht, NL has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-11-06

US20250340647A1

Chemistry; metallurgy

ANTIBODIES

#2 | 2024-11-28

US20240392032A1

Chemistry; metallurgy

ANTIBODIES

#3 | 2024-09-26

US20240317861A1

Chemistry; metallurgy

ANTIBODIES AGAINST PD-L1

#4 | 2023-11-23

US20230374131A1

Chemistry; metallurgy

HUMANIZED OR CHIMERIC CD3 ANTIBODIES

#5 | 2023-10-05

US20230312693A1

Chemistry; metallurgy

Agents, Uses and Methods for the Treatment of Synucleinopathy

#6 | 2023-08-17

US20230257479A1

Chemistry; metallurgy

BISPECIFIC ANTIBODIES BINDING TO 5T4 AND CD3 FOR USE IN TREATMENT OF CANCER

#7 | 2023-03-23

US20230089969A1

Chemistry; metallurgy

MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137

#8 | 2023-03-23

US20230087745A1

Chemistry; metallurgy

BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF

#9 | 2023-01-26

US20230027394A1

Chemistry; metallurgy

HUMANIZED OR CHIMERIC CD3 ANTIBODIES

#10 | 2022-12-08

US20220389101A1

Chemistry; metallurgy

HUMANIZED OR CHIMERIC CD3 ANTIBODIES

#11 | 2022-12-01

US20220380464A1

Chemistry; metallurgy

HUMANIZED OR CHIMERIC CD3 ANTIBODIES

#12 | 2022-10-13

US20220324980A1

Chemistry; metallurgy

ANTIBODIES

#13 | 2022-03-03

US20220064317A1

Chemistry; metallurgy

Multispecific antibodies against CD40 and CD137

#14 | 2022-02-17

US20220049013A1

Chemistry; metallurgy

Antibodies

#15 | 2022-02-17

US20220048999A1

Chemistry; metallurgy

Antibodies

#16 | 2022-02-03

US20220033510A1

Chemistry; metallurgy

Multispecific antibodies against CD40 and CD137

#17 | 2021-12-02

US20210369842A1

Human necessities

ANTIBODY FORMULATION

#18 | 2021-10-14

US20210317225A1

Chemistry; metallurgy

Multispecific antibodies against CD40 and CD137

#19 | 2021-09-23

US20210292418A1

Chemistry; metallurgy

ANTIBODIES

#20 | 2021-09-09

US20210277133A1

Chemistry; metallurgy

BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF

#21 | 2021-09-02

US20210269541A1

Chemistry; metallurgy

BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF

#22 | 2021-07-29

US20210230296A1

Chemistry; metallurgy

Antibodies

#23 | 2021-06-03

US20210163616A1

Chemistry; metallurgy

Binding agents binding to PD-L1 and CD137 and use thereof

#24 | 2021-05-20

US20210147522A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#25 | 2021-03-11

US20210070877A1

Chemistry; metallurgy

Antibodies

#26 | 2021-03-04

US20210061892A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#27 | 2021-02-25

US20210054057A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#28 | 2020-09-03

US20200277397A1

Chemistry; metallurgy

ANTIBODIES

#29 | 2020-08-06

US20200247899A1

Chemistry; metallurgy

Multispecific antibodies against CD40 and CD137

#30 | 2020-07-30

US20200239579A1

Chemistry; metallurgy

ANTIBODIES AGAINST PD-L1

#31 | 2020-06-25

US20200199231A1

Chemistry; metallurgy

BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20

#32 | 2020-06-25

US20200199229A1

Chemistry; metallurgy

Humanized or chimeric CD3 antibodies

#33 | 2020-05-28

US20200165349A1

Chemistry; metallurgy

Binding agents binding to PD-L1 and CD137 and use thereof

#34 | 2020-02-27

US20200062853A1

Chemistry; metallurgy

Methods of producing multispecific antibodies against CD40 and CD137

#35 | 2019-12-19

US20190382473A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#36 | 2019-12-05

US20190367595A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#37 | 2019-12-05

US20190367594A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#38 | 2019-09-19

US20190284278A1

Chemistry; metallurgy

Humanized or chimeric CD3 antibodies

#39 | 2018-06-28

US20180179271A1

Chemistry; metallurgy

Antibodies for the treatment of synucleinopathy

#40 | 2018-06-28

US20180179270A1

Chemistry; metallurgy

Antibodies for the treatment of synucleinopathy

#41 | 2018-05-10

US20180127492A1

Chemistry; metallurgy

Antibodies for the treatment of synucleinopathy

#42 | 2018-05-10

US20180127491A1

Chemistry; metallurgy

Antibodies for the treatment of synucleinopathy

#43 | 2017-12-14

US20170355767A1

Chemistry; metallurgy

Bispecific antibodies against CD3 and CD20

#44 | 2017-01-19

US20170015739A1

Chemistry; metallurgy

Agents, uses and methods for the treatment of synucleinopathy

#45 | 2016-11-17

US20160333095A1

Chemistry; metallurgy

Humanized or chimeric CD3 antibodies

InventorID:

1710932 ⎘